rs6897932 — IL7R T244I

Splicing variant in the IL-7 receptor alpha chain that shifts the balance toward soluble receptor, amplifying IL-7 signaling and raising susceptibility to multiple sclerosis and related autoimmune conditions

See your personal result for IL7R

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL7R T244I — The Soluble Receptor Switch That Tips T-Cell Balance

Interleukin-7 (IL-7) is an indispensable cytokine for T-cell development and homeostasis. Without adequate IL-7 signaling, the thymus cannot export naïve T cells11 thymus cannot export naïve T cells
IL-7 promotes survival and proliferation of naïve and memory T cells; deficiency causes lymphopenia and the peripheral T-cell pool shrinks. IL-7 acts through its receptor, IL-7Rα (CD127), encoded by the IL7R gene on chromosome 5. The T244I variant — rs6897932 — sits in exon 6 of IL7R, the exon that encodes the transmembrane anchor of the receptor. What looks like a simple amino acid change is actually a splicing switch: the C allele at this position increases the likelihood that exon 6 will be skipped during mRNA processing, producing a soluble, secreted form of the receptor (sIL7R) rather than the membrane-bound form. This shift in the membrane-to-soluble ratio has consequences for T-cell regulation and confers one of the most consistently replicated autoimmune risk signals outside the MHC.

The Mechanism

Exon 6 of IL7R encodes the transmembrane domain. When exon 6 is included in the mRNA, the resulting protein anchors to the T-cell surface as membrane-bound IL-7Rα. When exon 6 is skipped, the reading frame shifts to produce a soluble, secreted isoform (sIL7R) that circulates in the bloodstream. Healthy individuals produce both forms, but the ratio is tightly controlled.

The C allele at rs6897932 tips this balance toward exon skipping. Mechanistically, the C allele strengthens a cryptic branch-point sequence (BPS) within exon 622 the C allele strengthens a cryptic branch-point sequence (BPS) within exon 6
The BPS is followed by a polypyrimidine tract that recruits U2AF2 ectopically into the exon body rather than the canonical intronic location. U2AF2 binding to this exonic polypyrimidine tract recruits U2 snRNP components directly to the exon, assembling a silencing complex that promotes exon 6 exclusion from the mature transcript. The result: C-allele carriers produce a higher fraction of sIL7R and a lower fraction of membrane-bound receptor. In stimulated monocytes, CC homozygotes generate roughly three times more sIL7R33 three times more sIL7R
Mean sIL7R 3149 ng/ml in CC vs. 917 ng/ml in TT carriers after LPS stimulation (p = 4.7 × 10⁻¹⁵) than TT homozygotes.

Why does elevated sIL7R raise autoimmune risk? Circulating sIL7R forms complexes with IL-7, and rather than blocking IL-7 activity, these complexes potentiate IL-7's half-life and bioavailability44 potentiate IL-7's half-life and bioavailability
IL-7/sIL7R complexes are more stable than free IL-7, extending its functional lifespan in circulation. More available IL-7 drives increased T-cell survival and proliferation, expanding the T-cell pool in a way that can include self-reactive clones. Mouse models confirm the consequence: exogenous sIL7R exacerbates disease in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis.

The Evidence

The MS association was first established by Gregory et al. in 200755 Gregory et al. in 2007
Analysis of four independent datasets totaling >3,000 cases; overall P = 2.9 × 10⁻⁷, making IL7R one of the first confirmed non-MHC MS risk loci, who identified rs6897932 as a bona fide risk locus across four independent family-based and case-control datasets (combined P = 2.9 × 10⁻⁷). Two large meta-analyses have since quantified the effect: one covering 10 studies with 12,185 MS cases66 10 studies with 12,185 MS cases
The C/C genotype OR was 1.15 (95% CI 1.06–1.24; P = 0.0009) under a recessive model found the CC genotype confers OR 1.15 compared to CT/TT, while a larger analysis of 28 studies with 16,260 MS cases and 18,335 controls77 28 studies with 16,260 MS cases and 18,335 controls
Pooled ORs: recessive 1.13, dominant 1.17, allelic 1.11 (all P < 0.05) confirmed consistent associations across genetic models (allelic OR 1.11, homozygous OR 1.21). The association is strongest in European populations and was not replicated in Middle Eastern or most Asian cohorts, consistent with the lower frequency of the T protective allele in African and East Asian populations.

Beyond MS, the same rs6897932 locus has been associated with ankylosing spondylitis and primary biliary cirrhosis88 ankylosing spondylitis and primary biliary cirrhosis
Consistent with the broader pattern of immune dysregulation linked to elevated sIL7R. For type 1 diabetes, an independent replication study in Spanish and Dutch cohorts99 an independent replication study in Spanish and Dutch cohorts
301 Spanish T1D cases and 646 controls plus 429 Dutch cases and 720 controls; T/T genotype OR 0.18 for early-onset T1D (P = 0.02) found that TT homozygosity was strongly protective against early-onset T1D, suggesting the T allele's protection extends beyond MS to other T-cell-mediated autoimmune diseases.

Practical Implications

The effect size for MS from this variant alone is modest (OR 1.11–1.21 per allele), but it operates on top of other genetic and environmental risk factors. Carriers of CC genotype — the most common configuration in Europeans (~54%) — benefit from awareness of MS early warning signs and from factors known to reduce MS risk, such as maintaining adequate vitamin D levels, avoiding smoking, and being aware of Epstein-Barr virus (EBV) serostatus, since EBV infection is the strongest known environmental trigger for MS. While no intervention can directly modify IL7R splicing in a clinical setting, lifestyle factors that reduce systemic inflammatory burden lower the threshold at which elevated sIL7R promotes autoimmune activation.

For CT heterozygotes, the excess risk over baseline is small and no specific intervention is warranted beyond standard health awareness. For CT and CC carriers with a personal or family history of autoimmune disease, proactive monitoring for early neurological symptoms and autoimmune markers is prudent.

Interactions

The closest documented genetic interaction involves rs2104286 in IL2RA (the interleukin-2 receptor alpha chain, CD25). Both IL7R and IL2RA are essential components of T-cell homeostatic signaling, and both contain well-replicated MS susceptibility variants. Individuals who carry risk alleles at both loci — rs6897932 C allele and rs2104286 T allele — are expected to have additive or supra-additive elevations in MS risk, since IL-7 and IL-2 operate in partially independent pathways governing T-cell survival and regulatory T-cell maintenance. Individuals carrying risk alleles at rs6897932 (IL7R) and rs2104286 (IL2RA) represent a subset warranting closer autoimmune monitoring.

A second epistatic interaction has been characterized with rs2523506 in DDX39B: the A allele of DDX39B reduces expression of this splicing activator, further promoting exon 6 skipping at IL7R. Individuals homozygous for risk alleles at both IL7R (CC) and DDX39B (AA) showed OR = 2.75 (95% CI 1.86–4.08) for MS1010 OR = 2.75 (95% CI 1.86–4.08) for MS
Combined risk far exceeds either variant alone; P = 4.5 × 10⁻⁷ for the epistatic interaction, a substantially larger effect than either variant alone.

Genotype Interpretations

What each possible genotype means for this variant.

TT Protective Receptor Balance Normal

Two copies of the protective allele — lowest sIL7R production and reduced MS susceptibility from this locus

You carry two copies of the T allele, the genotype associated with the lowest production of soluble IL-7 receptor. Your IL7R exon 6 is included more reliably in mRNA transcripts, producing predominantly membrane-bound receptor and less circulating sIL7R. This is the least common genotype in Europeans (approximately 7%) and confers the lowest MS susceptibility from this locus. Research in type 1 diabetes showed TT homozygosity had a strongly protective effect in early-onset disease (OR 0.18), suggesting this genotype's protection extends across T-cell- mediated autoimmune conditions.

CT Partial Soluble Receptor Elevation Intermediate

One copy of each allele — moderately increased sIL7R and slightly elevated MS susceptibility

Heterozygotes produce an intermediate ratio of soluble to membrane-bound IL-7Rα. One C allele increases exon 6 skipping on that chromosome while the T allele maintains near-normal exon inclusion on the other. The net effect is intermediate sIL7R production. Genetic modeling in MS meta-analyses places CT risk between CC and TT, consistent with a codominant pattern. The dominant model (CC+CT vs TT) yields OR approximately 1.15, suggesting even one C allele confers measurable though modest risk. For most other autoimmune conditions associated with this SNP (ankylosing spondylitis, primary biliary cirrhosis, T1D), the CT genotype sits at intermediate risk comparable to the general population.

CC Increased Soluble Receptor High Risk

Two copies of the risk allele — highest sIL7R production and greatest MS susceptibility from this locus

The CC genotype maximizes IL7R exon 6 skipping, producing the highest fraction of soluble receptor and the lowest proportion of membrane-bound IL-7Rα. Soluble IL7R forms stable complexes with IL-7 that extend its circulating half-life, driving greater T-cell survival and proliferation. Studies in stimulated monocytes showed CC carriers produce approximately 3.4-fold more sIL7R than TT carriers after innate immune stimulation, representing a dramatic quantitative difference in IL-7 signaling capacity.

In the context of MS, elevated sIL7R likely expands self-reactive T-cell clones that would otherwise be eliminated by regulatory mechanisms. The association is most pronounced in European populations: meta-analyses consistently find recessive ORs of 1.13–1.15 for CC vs CT/TT genotypes. For early-onset type 1 diabetes, the converse is true — CC individuals lack the protective T-allele effect, which showed OR 0.18 in early-onset T1D cases, suggesting the T allele's protection extends broadly across T-cell-dependent autoimmune conditions.

Epistatic interactions amplify the CC risk: individuals who also carry the DDX39B rs2523506 AA genotype (reduced splicing activator expression) show OR 2.75 for MS, far exceeding the effect of either variant alone.